These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

693 related items for PubMed ID: 29377877

  • 21. Predictive factors of spontaneous CMV DNAemia clearance in kidney transplantation.
    Noble J, Gatault P, Sautenet B, Gaudy-Graffin C, Beby-Defaux A, Thierry A, Essig M, Halimi JM, Munteanu E, Alain S, Buchler M.
    J Clin Virol; 2018; 99-100():38-43. PubMed ID: 29306112
    [Abstract] [Full Text] [Related]

  • 22. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
    Abate D, Saldan A, Fiscon M, Cofano S, Paciolla A, Furian L, Ekser B, Biasolo MA, Cusinato R, Mengoli C, Bonfante L, Rossi B, Rigotti P, Sgarabotto D, Barzon L, Palù G.
    J Infect Dis; 2010 Aug 15; 202(4):585-94. PubMed ID: 20594105
    [Abstract] [Full Text] [Related]

  • 23. CMV mismatch does not affect patient and graft survival in UK renal transplant recipients.
    Johnson RJ, Clatworthy MR, Birch R, Hammad A, Bradley JA.
    Transplantation; 2009 Jul 15; 88(1):77-82. PubMed ID: 19584684
    [Abstract] [Full Text] [Related]

  • 24. A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients.
    Reischig T, Vlas T, Kacer M, Pivovarcikova K, Lysak D, Nemcova J, Drenko P, Machova J, Bouda M, Sedivcova M, Kormunda S.
    J Am Soc Nephrol; 2023 May 01; 34(5):920-934. PubMed ID: 36749127
    [Abstract] [Full Text] [Related]

  • 25. Different impact of rATG induction on CMV infection risk in D+R- and R+ KTRs.
    Kaminski H, Jarque M, Halfon M, Taton B, Di Ascia L, Pfirmann P, Visentin J, Garrigue I, Déchanet-Merville J, Moreau JF, Crespo E, Montero N, Melilli E, Meneghini M, Pascual M, Couzi L, Manuel O, Bestard O, Merville P.
    J Infect Dis; 2019 Jul 31; 220(5):761-771. PubMed ID: 31157865
    [Abstract] [Full Text] [Related]

  • 26. Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight-based dosed valganciclovir prophylaxis.
    Liverman R, Serluco A, Nance G, George R, Rodriguez DS, Deshpande S, Mao C, Garro R, Yildirim I.
    Pediatr Transplant; 2023 Jun 31; 27(4):e14493. PubMed ID: 36945819
    [Abstract] [Full Text] [Related]

  • 27. Low-dose valganciclovir prohylaxis is efficacious and safe in cytomegalovirus seropositive heart transplant recipients with anti-thymocyte globulin.
    Eriksson M, Jokinen JJ, Söderlund S, Hämmäinen P, Lommi J, Lemström K.
    Transpl Infect Dis; 2018 Jun 31; 20(3):e12868. PubMed ID: 29512249
    [Abstract] [Full Text] [Related]

  • 28. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
    Myhre HA, Haug Dorenberg D, Kristiansen KI, Rollag H, Leivestad T, Asberg A, Hartmann A.
    Transplantation; 2011 Jul 27; 92(2):217-23. PubMed ID: 21685829
    [Abstract] [Full Text] [Related]

  • 29. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR, Sawinski D, Blumberg E, Galanakis N, Bloom RD, Trofe-Clark J.
    Transpl Infect Dis; 2015 Apr 27; 17(2):163-73. PubMed ID: 25661673
    [Abstract] [Full Text] [Related]

  • 30. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
    Lo A, Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Kisilisik AT, Trofe J, Alloway RR, Gaber LW, Gaber AO.
    Transpl Infect Dis; 2001 Mar 27; 3(1):8-15. PubMed ID: 11429034
    [Abstract] [Full Text] [Related]

  • 31. Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus.
    Devresse A, Leruez-Ville M, Scemla A, Avettand-Fenoel V, Morin L, Lebreton X, Tinel C, Amrouche L, Lamhaut L, Timsit MO, Zuber J, Legendre C, Anglicheau D.
    Transpl Infect Dis; 2018 Apr 27; 20(2):e12846. PubMed ID: 29360195
    [Abstract] [Full Text] [Related]

  • 32. Six-month low-dose valganciclovir prophylaxis in cytomegalovirus D+/R- kidney transplant patients receiving thymoglobulin induction.
    Luan FL.
    Transplant Proc; 2013 Apr 27; 45(1):175-7. PubMed ID: 23267799
    [Abstract] [Full Text] [Related]

  • 33. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients.
    Lisboa LF, Preiksaitis JK, Humar A, Kumar D.
    Transplantation; 2011 Nov 15; 92(9):1063-8. PubMed ID: 21878838
    [Abstract] [Full Text] [Related]

  • 34. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.
    Selvey LA, Lim WH, Boan P, Swaminathan R, Slimings C, Harrison AE, Chakera A.
    BMC Infect Dis; 2017 Jul 17; 17(1):501. PubMed ID: 28716027
    [Abstract] [Full Text] [Related]

  • 35. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.
    Chiereghin A, Potena L, Borgese L, Gibertoni D, Squarzoni D, Turello G, Petrisli E, Piccirilli G, Gabrielli L, Grigioni F, Lazzarotto T.
    J Clin Microbiol; 2018 Apr 17; 56(4):. PubMed ID: 29305542
    [Abstract] [Full Text] [Related]

  • 36. Early cytomegalovirus DNAemia and antiviral dose adjustment in high vs intermediate risk kidney transplant recipients.
    Schaenman J, Phonphok K, Spanuchart I, Duong T, Sievers TM, Lum E, Reed EF, Bunnapradist S.
    Transpl Infect Dis; 2021 Feb 17; 23(1):e13457. PubMed ID: 32892447
    [Abstract] [Full Text] [Related]

  • 37. Post-renal transplant cytomegalovirus infection: study of risk factors.
    Kute VB, Vanikar AV, Shah PR, Gumber MR, Patel HV, Godara SM, Munjappa BC, Sainaresh VV, Engineer DP, Jain SH, Modi PR, Shah VR, Trivedi VB, Trivedi HL.
    Transplant Proc; 2012 Apr 17; 44(3):706-9. PubMed ID: 22483473
    [Abstract] [Full Text] [Related]

  • 38. The impact of viral load and time to onset of cytomegalovirus replication on long-term graft survival after kidney transplantation.
    Reischig T, Kacer M, Hruba P, Jindra P, Hes O, Lysak D, Bouda M, Viklicky O.
    Antivir Ther; 2017 Apr 17; 22(6):503-513. PubMed ID: 28091392
    [Abstract] [Full Text] [Related]

  • 39. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients.
    Huurman VA, Kalpoe JS, van de Linde P, Vaessen N, Ringers J, Kroes AC, Roep BO, De Fijter JW.
    Diabetes Care; 2006 Apr 17; 29(4):842-7. PubMed ID: 16567825
    [Abstract] [Full Text] [Related]

  • 40. Burden of cytomegalovirus DNAemia among pediatric renal transplant patients on antiviral prophylaxis: A hospital-based analysis.
    Mehta K, Al-Yabes O, Allen A, Williams A, Petrich A, Langlois V, Hébert D, Allen U.
    Pediatr Transplant; 2020 Feb 17; 24(1):e13650. PubMed ID: 31891234
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.